Due to restrictions related to Danish law and protecting patient privacy, the combined set of data as used in this study can only be made available through a trusted third party, Statistics Denmark. This state organisation holds the data used for this study. University-based Danish scientific organisations can be authorized to work with data within Statistics Denmark and such organisation can provide access to individual scientists inside and outside of Denmark. Requests for data may be sent to Statistics Denmark: <forskningsservice@dst.dk> or +45 39 17 31 32.

Introduction {#sec005}
============

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) represent a new and increasingly used class of oral antihyperglycemic drugs for type 2 diabetes (T2D) \[[@pone.0229621.ref001]\]. These agents currently include 4 agents: dapagliflozin, canagliflozin, empagliflozin, ertugliflozine, and combinations of these SGLT2i with metformin or other antihyperglycemic drugs \[[@pone.0229621.ref002]--[@pone.0229621.ref004]\]. Similarly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently including exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide, and paired injectables in combinations with other antihyperglycemic drugs, as a class are increasingly used in the treatment of T2D over the last decade \[[@pone.0229621.ref005]--[@pone.0229621.ref007]\]. While metformin has remained the recommended initial antihyperglycemic drug for most patients with T2D, international (and Danish) guidelines until now have recommended a free choice among several second or third line treatment options, based on an individualised treatment approach \[[@pone.0229621.ref008]\]. In the most recent years, the prescription patterns of SGLT2i and GLP-1RAs in real-world settings may have been increasingly influenced by landmark cardiovascular (CV) outcome trials instigated by regulatory authorities to promote patient safety \[[@pone.0229621.ref009]\], but data on incident utilization trends are scarce. In 2015, the empagliflozin EMPA-REG OUTCOME trial \[[@pone.0229621.ref010]\] showed a reduced risk of CV outcomes, CV mortality, and all-cause mortality in patients with T2D with existing CV disease. In 2017, the canagliflozin CANVAS trial program \[[@pone.0229621.ref011]\] showed a reduced risk of major adverse CV events in patients with T2D and high CV risk. For GLP-1RAs, the 2016 liraglutide LEADER trial showed a reduced risk of CV outcomes, CV mortality, and all-cause mortality in patients with high CV risk. A reduced risk of CV outcomes was also observed in similar patients receiving semaglutide in the SUSTAIN-6 trial in 2016 \[[@pone.0229621.ref012],[@pone.0229621.ref013]\]. Therefore, in the most recent updates to the EASD/ADA and Danish guidelines from 2018 and 2019 \[[@pone.0229621.ref014]--[@pone.0229621.ref016]\], initiation of a SGLT2i or a GLP-1RA with proven CV benefit has been recommended for patients with T2D and clinical CV disease, with currently strongest evidence available for liraglutide and empagliflozin \[[@pone.0229621.ref014]--[@pone.0229621.ref016]\].

There are scarce population-based data on how the initiation rates and clinical profiles of initiators of SGLT2i or GLP-1RA have evolved in real-world settings before and after publication of key trial results \[[@pone.0229621.ref003]--[@pone.0229621.ref007],[@pone.0229621.ref009]\]. Linked Danish population-based healthcare databases provide a unique opportunity to characterize recent SGLT2i and GLP-1RAs utilization trends in Denmark, and to clinically describe all individuals with incident use of these drugs.

We therefore aimed to examine trends in initiation incidence rates, medication patterns at baseline, and baseline patient characteristics at the time of first drug initiation among SGLT2i and GLP-1RA new users, focusing on changes from 2014 to 2017. We compared the results to time trends for new DPP-4i users, a drug class without proven CV benefit. We hypothesized that publication of key CV outcome trial results and new drug labels during 2014--2017 may have influenced both the overall new SGLT2i and GLP-1RA user incidence, increased the proportion of patients who initiate these agents early in the course of diabetes (e.g., as second-line drugs after metformin), and increased the proportion who had preexisting atherosclerotic cardiovascular disease (ASCVD) at the time of drug initiation.

Materials and methods {#sec006}
=====================

Setting and source population {#sec007}
-----------------------------

We conducted nationwide cross-sectional analyses of linked Danish population-based healthcare databases to characterize all initiators of SGLT2i and GLP-1RA in Denmark during 2014 through 2017. We first identified a source population consisting of all individuals who lived in Denmark and redeemed a prescription of an antihyperglycemic drug in the period 1995--2017, defined as filling one or more prescriptions for: metformin, sulfonylurea, thiazolidinedione, SGLT2i, GLP-1RA, DPP-4i, insulin, alpha-glucosidase inhibitor, other oral antihyperglycemic drugs, or combination products, according to the Anatomical Therapeutic Chemical (ATC) classification system (codes A10A, A10B). \[[@pone.0229621.ref017]\]. Diabetic patients who under the age of 30 used insulin as mono-therapy and never used oral antihyperglycemic medications were excluded as likely type 1 diabetes patients \[[@pone.0229621.ref018],[@pone.0229621.ref019]\]. The remaining individuals were defined as having T2D. Within this population of incident initiators of antihyperglycemic drugs for T2D 1995--2017, all incident first-time users of SGLT2i, GLP-1RA, and DPP-4i in the period 1 January 2014 to 31 December 2017 (i.e., no previous use of the respective drug recorded between 1995 and 2014) were identified. In our main analysis, we disregarded initiation of the GLP-1RA liraglutide brand-named Saxenda^®^ as an inclusion criterion for the GLP-1RA initiator cohort, because Saxenda^®^ (liraglutide 3.0 mg daily) was approved as a treatment for chronic weight management in obese patients in 2015. In an additional sensitivity analysis, we also included Saxenda^®^ initiators in the GLP-1RA initiator cohort.

Data sources {#sec008}
------------

The Civil Registration System (CRS) holds records of central personal registry (CPR)-number, address, marital status, emigration and immigration status, and date of death (if any) of the entire population of Denmark (current population 5.7 mio) since 1968. This system can be used to unambiguously link all Danish registries containing CPR-numbers \[[@pone.0229621.ref020]\]. The Danish National Patient Register (DNPR) includes information of all hospitalized patients since 1977 and on outpatient hospital contacts since 1995. The register contains information about the date of admission, discharge, diagnosis codes and surgical procedures. From 1994 onwards they have been coded according to International Statistical Classification of Diseases and Related Health Problems 10^th^ revision (ICD-10) \[[@pone.0229621.ref021]\]. The Danish National Prescription Registry covers all drug prescriptions redeemed at any pharmacy in Denmark since 1995, including patient's identifier, date of sale, type of drug, and universal product number (*Varenummer*), which encodes medication name \[[@pone.0229621.ref022]\]. Computerized clinical biochemistry test results have been kept in the LABKA Database for all samples taken in primary or secondary care among persons living in North and Central Denmark (apprx 30% of the total Danish population) beginning in 1997 and complete from 2000 \[[@pone.0229621.ref017],[@pone.0229621.ref023],[@pone.0229621.ref024]\].

Characteristics of SGLT2i, GLP-1RA, and DPP-4i initiators {#sec009}
---------------------------------------------------------

For all patients with a first prescription of SGLT2i, GLP-1RA, or DPP-4i in 2014--2017 (the index date), either as their first ever antihyperglycemic drug prescription or as intensification or replacement therapy for previous antihyperglycemic drug use (e.g. metformin), we ascertained data on age, gender, place of residence, and marital status. Using the DNPR, we assessed a complete hospital contact history for each individual for any previous hospital-diagnosed ASCVD, both overall and for individual conditions (i.e., atherosclerotic heart disease including myocardial infarction, angina pectoris, or any coronary surgery; atherosclerotic cerebrovascular disease including stroke, TCI, or thrombolysis/thrombectomy; or peripheral vascular disease including claudication, vascular surgery, extremity amputation procedures). We also assessed pre-existing hospital-diagnosed heart failure, renal disease, medical obesity, and a number of other important comorbidities including COPD, cancer, liver disease, alcoholism-related conditions, and previous infections (see [S1 File](#pone.0229621.s001){ref-type="supplementary-material"} for codes). We assessed the comorbidity burden using the Charlson comorbidity index (CCI) \[[@pone.0229621.ref025]\], and calculated a total score for each patient (no comorbidities \[score = 0\], moderate comorbidity burden \[score = 1\], severe comorbidity burden \[score = 2\] or very severe comorbidity burden \[score \> 2\]). We further assessed use of any comedications on the index date (type and number of other antihyperglycemic therapies, any CV medications including antihypertensives, antiplatelet therapy, or lipid-lowering drugs, and glucocorticoids), and diabetes duration on the index date (years since first ever recorded diabetes hospital diagnosis or diabetes therapy start). For the regional subcohort in North and Central Denmark with available laboratory data (\~30% of the T2D population), we also ascertained HbA~1c~ (last measured value within 12 months), eGFR based on last measured creatinine (calculated using CKI-EPI equation \[[@pone.0229621.ref026]\]), and LDL cholesterol values.

Ethics {#sec010}
------

The study was approved by the Danish Data Protection Agency. Analyses were conducted on pseudonymized data at the Danish Health Data Authority. The study was purely registry-based and did not involve any contact with patients or interventions; therefore, according to Danish legislation, no informed consent or approval from the health research ethics committee was required.

Statistical methods {#sec011}
-------------------

For all graphical time trend analyses, we plotted dates (quarter) of the following events on our timeline: TECOS: Sitagliption (DPP-4i) showed non-inferiority to placebo (June 2015) \[[@pone.0229621.ref025]\]; Obesity label: Liraglutide 3.0 mg daily launched as treatment for obesity (August 2015); EMPA-REG OUTCOME: empagliflozin showed CV and CV/all-cause mortality benefits (September 2015) \[[@pone.0229621.ref004]\], LEADER: liraglutide showed CV and CV/all-cause mortality benefits (June 2016) \[[@pone.0229621.ref006]\]; CANVAS: canagliflozin showed CV benefits (June 2017) \[[@pone.0229621.ref005]\]; Empagliflozin launched as treatment in T2D patients with CVD (CV label) (January 2017); Liraglutide launched as treatment in T2D patients with CVD (CV label) (June 2017).

Initiation incidence {#sec012}
--------------------

Firstly, based on redeemed prescriptions 1995--2017, we calculated and graphically plotted the number of first ever users of SGLT2i, GLP-1RA, or DPP-4i with 95% confidence intervals, per 100,000 inhabitants in Denmark for each calendar year, of each of the study medications by calendar year and quarter from 2014--2017. We examined increases between calendar year 2014 and 2017 in incident users of study medications per 100,000 person-years. We repeated these analysis and plots for individual drugs, within the drug classes.

Baseline medication patterns {#sec013}
----------------------------

Secondly, based on redeemed antihyperglycemic therapy prescriptions 100 days prior to the index date (typical pack size of antihyperglycemic drugs in Denmark 90 to 100 daily doses), we calculated and graphically plotted the proportions who, prior to initiating treatment with SGLT2i, GLP-1RA, or DPP-4i, received: no antihyperglycemic therapy, monotherapy, dual therapy, and triple or higher (multiple) therapy, by calendar year and quarter from 2014--2017.

Baseline characteristics {#sec014}
------------------------

Thirdly, for each of the index drugs, we calculated the proportion of all initiators in the total study period having each of the baseline characteristics. We calculated prevalence ratios comparing GLP-1RA and SGLT2i with DPP-4i initiators as a common reference group, using modified Poisson regression to adjust for age and sex (in order to be able to evaluate if a difference in prevalence ratios was more than could be attributed to the difference arising from age and sex difference found between the groups). Next, we examined if proportions with ASCVD and other important patient characteristics at initiation changed in timely relation to CV outcome trial publication, new drug labels, or other main events during the period 2014--2017. Changes in age- and gender-adjusted prevalence ratios (aPRs) of characteristics within each drug class internally, using the last study year 2017 versus 2014 as the reference year was calculated. For selected pre-defined characteristics of special interest (any ASCVD, HF, stroke, MI, and hospital-coded medical obesity) we graphically plotted the evolving proportion of initiators with these characteristics for each of the three study medication classes, with 95% confidence intervals, by calendar year and quarter from 2014--2017. For the same time periods, we calculated the proportion (with 95% confidence intervals) of patients that had redeemed a prescription for antihypertensive treatment and statins one year prior to initiation of an index drug. Since Saxenda^®^ (liraglutide 3.0 mg daily, obesity treatment label) may be sometimes used in clinical practice as antihyperglycemic treatment in patients who are both obese and have T2D, we did a sensitivity analysis also including patients initating Saxenda^®^ in the GLP1-RA cohort.

Results {#sec015}
=======

We identified 25,070 new first-time SGLT2i initiators, 14,671 first-time GLP-1RA initiators, and 34,079 first-time DPP-4i initiators in Denmark during 2014--2017. As a point of comparison, the total number of unique prevalent users in our data during 2014--2017 was 32,091 for SGLT2i, 37,282 for GLP-1RA, and 64,613 for DPP-4i. During the four years study period, the incidence of SGLT2i initiators increased 3.6-fold, from 53 / 100,000 person-years (PY) in 2014 to 172 / 100,000 PY in 2017 (quarterly changes can be seen in [Fig 1](#pone.0229621.g001){ref-type="fig"}). In comparison, the number of GLP-1RA initiators increased 1.5-fold, while the number of DPP-4i initiators remained very stable (1.05-fold increase) throughout 2014--2017 ([Fig 1](#pone.0229621.g001){ref-type="fig"}). Liraglutide was almost exclusively used in the GLP-1RA class throughout 2014--2017, while empagliflozin quickly became the most commonly prescribed SGLT2i following the EMPAREG outcome trial ([S1 File](#pone.0229621.s001){ref-type="supplementary-material"}).

![Quarterly number of initiators of DPP-4i, GLP-1RA, and SGLT2i in Denmark, 2014--2017.\
DPP-4i: dipeptidyl peptidase-4 inhibitor; GLP-1RA: glucagon-like peptide-1 receptor agonists; SGLT2i: sodium-glucose cotransporter 2 inhibitors; TECOS: Sitagliptin (DPP-4i) showed non-inferiority to placebo \[[@pone.0229621.ref035]\]; Lira obesity label: Liraglutide 3 mg launched as treatment for obesity; EMPA-REG OUTCOME: empagliflozin showed CV and CV/all-cause mortality benefits \[[@pone.0229621.ref010]\], LEADER: liraglutide showed CV and CV/all-cause mortality benefits \[[@pone.0229621.ref012]\]; CANVAS: canagliflozin showed CV benefits \[[@pone.0229621.ref011]\].](pone.0229621.g001){#pone.0229621.g001}

[Fig 2](#pone.0229621.g002){ref-type="fig"} shows that early on during the 2014--2017 period, SGLT2i was most often prescribed as third-line treatment; however, the likelihood of initiating SGLT2i as second-line therapy increased substantially between 2014 and 2017. Use of SGLT2i in patients previously receiving antihyperglycemic monotherapy increased from 22% in 2015 Q3 to 36% in 2017 Q4. In comparison, initiation lines were rather stable for GLP-1RA initiators during 2014--2017 ([Fig 2](#pone.0229621.g002){ref-type="fig"}). When also including patients iniating Saxenda^®^ (liraglutide 3.0 mg daily, obesity treatment label) in the analysis, GLP-1RA use as monotherapy increased from 2015 and onwards ([S1 File](#pone.0229621.s001){ref-type="supplementary-material"}). DPP-4i were predominantly and consistently used as second-line therapy throughout the study period ([Fig 2](#pone.0229621.g002){ref-type="fig"}).

![Time trends in proportions using various baseline glucose-lowering drug regimens at the time of initiation of DPP-4i, GLP-1RA, and SGLT2i, respectively.\
Graphs show the proportion of patients who--at the time of their first initiation of either DPP-4i, GLP-1RA, or SGLT2i --are on no other GLD treatment (red graph), on another GLD monotherapy (green graph), on dual GLD therapy (blue graph), or on triple GLD therapy (purple graph). DPP-4i: dipeptidyl peptidase-4 inhibitor; GLP-1RA: glucagon-like peptide-1 receptor agonists; SGLT2i: sodium-glucose cotransporter 2 inhibitors; TECOS: Sitagliptin (DPP-4i) showed non-inferiority to placebo \[[@pone.0229621.ref035]\]; Lira obesity label: Liraglutide 3 mg launched as treatment for obesity; EMPA-REG OUTCOME: empagliflozin showed CV and CV/all-cause mortality benefits \[[@pone.0229621.ref010]\], LEADER: liraglutide showed CV and CV/all-cause mortality benefits \[[@pone.0229621.ref012]\]; CANVAS: canagliflozin showed CV benefits \[[@pone.0229621.ref011]\].](pone.0229621.g002){#pone.0229621.g002}

Overall, prevalence of common diabetes complications and other comorbidities at drug initiation was rather similar between the three drug groups. For example, a history of peripheral vascular disease was present in 8.7% of SGLT2i, 8.5% of GLP-1RA, and 8.3% of DPP-4i initiators. However, patients who initiated SGLT2i (median age 61 years \[IQR 53--69\]) or GLP-1RA (59 years \[IQR 51--68\]) were younger than DPP-4i initiators (66 years \[IQR 56--74\]) ([Table 1](#pone.0229621.t001){ref-type="table"}). At the same time, SGLT2i initiators had a longer diabetes history at baseline (median 8.0 years \[IQR 4.6--12.4\]) than GLP-1RA (6.7 years \[IQR 3.3--11.2\] or DPP-4i initiators (5.4 years \[IQR 2.1--9.6\]) ([Table 1](#pone.0229621.t001){ref-type="table"}). During 2014--2017, any atherosclerotic ASCVD at baseline was present in 29% of SGLT2i initiators, 28% of GLP-1RA initiators, and 30% of DPP-4i initiators. After controlling for differences in gender and in particular for the younger age in SGLT2i and GLP-1RA initiators, this corresponded to adjusted prevalence ratios (aPRs) for ASCVD of 1.09 (95% CI 1.06--1.12) for SGLT2i and 1.13 (95% CI 1.10--1.16) for GLP-1RA initiators, versus the reference group of DPP-4i initiators. Prevalence proportions and aPRs for ischemic heart disease, cerebrovascular disease, heart failure, and for a number of other comorbidities at baseline are also shown in [Table 1](#pone.0229621.t001){ref-type="table"}.

10.1371/journal.pone.0229621.t001

###### Clinical characteristics among real-world initiators of GLP-1RA, SGLT2i and DPP-4i in Denmark, 2014--2017.

![](pone.0229621.t001){#pone.0229621.t001g}

                                                                                                GLP-1RA                 SGLT2i                      DPP-4i                                                
  --------------------------------------------------------------------------------------------- --------- ------------- ------------------- ------- ------------ ------------------- ------- ------------ ------------------
  **Sex**                                                                                                                                                                                                 **aPR (95% CI)**
  female                                                                                        6435      44.2          1.11 (1.08--1.13)   9621    38.4         0.96 (0.94--0.98)   13628   40.0         1.00 (ref)
  male                                                                                          8136      55.8          0.93 (0.91--0.94)   15449   61.6         1.03 (1.02--1.04)   20451   60.0         1.00 (ref)
  **Age**                                                                                                                                                                                                 
  0--29                                                                                         270       1.9           3.12 (2.60--3.74)   162     0.6          1.12 (0.91--1.38)   198     0.6          1.00 (ref)
  30--59                                                                                        7157      49.1          1.42 (1.39--1.45)   11303   45.1         1.30 (1.28--1.33)   11788   34.6         1.00 (ref)
  60--69                                                                                        4351      29.9          1.06 (1.03--1.10)   8042    32.1         1.13 (1.11--1.16)   9611    28.2         1.00 (ref)
  70+                                                                                           2793      19.2          0.52 (0.50--0.54)   5563    22.2         0.61 (0.59--0.62)   12482   36.6         1.00 (ref)
  Median Age (IQR)                                                                              59        (51--68)                          61      (53--69)                         66      (56--74)     1.00 (ref)
  **Region of residence**                                                                                                                                                                                 
  Capital Region                                                                                4160      28.5          0.96 (0.93--0.99)   7706    30.7         1.03 (1.00--1.05)   10215   30.0         1.00 (ref)
  Central Denmark Region                                                                        3218      22.1          0.99 (0.95--1.03)   5429    21.7         0.97 (0.94--1.00)   7549    22.2         1.00 (ref)
  North Denmark Region                                                                          1433      9.8           0.87 (0.82--0.92)   2428    9.7          0.85 (0.81--0.90)   3889    11.4         1.00 (ref)
  Region Zealand                                                                                2512      17.2          1.14 (1.09--1.19)   4355    17.4         1.14 (1.10--1.18)   5211    15.3         1.00 (ref)
  Southern Denmark                                                                              3248      22.3          1.04 (1.00--1.08)   5152    20.6         0.97 (0.94--1.00)   7215    21.2         1.00 (ref)
  **Diabetes duration**                                                                                                                                                                                   
  0 days                                                                                        442       3.0           0.68 (0.61--0.75)   248     1.0          0.22 (0.19--0.25)   1375    4.0          1.00 (ref)
  0-\<2 year                                                                                    2025      13.9          0.56 (0.54--0.59)   2540    10.1         0.45 (0.43--0.47)   6890    20.2         1.00 (ref)
  2-\<5 years                                                                                   2968      20.4          0.78 (0.75--0.81)   4183    16.7         0.68 (0.65--0.70)   7845    23.0         1.00 (ref)
  5-\<10 years                                                                                  4731      32.5          1.11 (1.08--1.15)   8741    34.9         1.20 (1.17--1.23)   9963    29.2         1.00 (ref)
  10+ years                                                                                     4405      30.2          1.59 (1.55--1.64)   9358    37.3         1.87 (1.83--1.92)   8006    23.5         1.00 (ref)
  **Median T2D duration**                                                                       6.7       (3.3--11.2)                       8.0     (4.6--12)                        5.4     (2.1--9.6)   1.00 (ref)
  **ASCVD**                                                                                     4085      28.0          1.13 (1.10--1.16)   7241    28.9         1.09 (1.06--1.12)   10370   30.4         1.00 (ref)
  **Myocardial Infarction**                                                                     2989      20.5          1.17 (1.12--1.21)   5328    21.3         1.13 (1.09--1.16)   7425    21.8         1.00 (ref)
  **Cerebrovascular disease**                                                                   1110      7.6           0.94 (0.88--1.00)   1971    7.9          0.90 (0.86--0.95)   3590    10.5         1.00 (ref)
  **Abdominal and peripheral vascular disease**                                                 1245      8.5           1.30 (1.22--1.39)   2173    8.7          1.23 (1.17--1.30)   2841    8.3          1.00 (ref)
  **Diabetic retinopathy**                                                                      2640      18.1          1.20 (1.15--1.25)   5190    20.7         1.29 (1.25--1.33)   6848    20.1         1.00 (ref)
  **Diabetic nephropathy**                                                                      1097      7.5           1.00 (0.94--1.07)   1548    6.2          0.77 (0.73--0.82)   3151    9.2          1.00 (ref)
  **Diabetic neuropathy**                                                                       1060      7.3           1.60 (1.49--1.72)   2058    8.2          1.70 (1.60--1.81)   1881    5.5          1.00 (ref)
  **Comorbidity level** [†](#t001fn001){ref-type="table-fn"}                                                                                                                                              
  0                                                                                             9024      61.9          1.00 (0.98--1.01)   15909   63.5         1.06 (1.05--1.07)   19272   56.6         1.00 (ref)
  1                                                                                             2804      19.2          1.12 (1.07--1.16)   4802    19.2         1.09 (1.05--1.12)   6263    18.4         1.00 (ref)
  2                                                                                             1603      11.0          1.08 (1.02--1.14)   2609    10.4         0.97 (0.92--1.01)   4318    12.7         1.00 (ref)
  \>=3                                                                                          1140      7.8           0.90 (0.85--0.96)   1750    7.0          0.74 (0.70--0.78)   4226    12.4         1.00 (ref)
  **Chronic heart failure**                                                                     914       6.3           1.06 (0.99--1.14)   1466    5.8          0.90 (0.85--0.96)   2768    8.1          1.00 (ref)
  **Atrial fibrillation**                                                                       1113      7.6           1.09 (1.02--1.16)   1830    7.3          0.94 (0.89--0.99)   3746    11.0         1.00 (ref)
  **Hypertension**                                                                              6044      41.5          1.24 (1.21--1.27)   10313   41.1         1.19 (1.16--1.21)   13385   39.3         1.00 (ref)
  **COPD**                                                                                      1511      10.4          1.10 (1.03--1.16)   2242    8.9          0.93 (0.88--0.98)   3551    10.4         1.00 (ref)
  **Cancer**                                                                                    1208      8.3           1.01 (0.95--1.07)   2083    8.3          0.94 (0.89--0.99)   3964    11.6         1.00 (ref)
  **Renal Disease**                                                                             832       5.7           0.94 (0.87--1.02)   1305    5.2          0.84 (0.78--0.89)   2176    6.4          1.00 (ref)
  **Rheumatic disease**                                                                         518       3.6           1.09 (0.98--1.20)   728     2.9          0.88 (0.81--0.97)   1260    3.7          1.00 (ref)
  **Osteoarthritis**                                                                            2835      19.5          1.26 (1.21--1.31)   4643    18.5         1.15 (1.11--1.19)   6435    18.9         1.00 (ref)
  **Osteoporosis/fracture**                                                                     203       1.4           0.82 (0.70--0.95)   332     1.3          0.72 (0.64--0.82)   916     2.7          1.00 (ref)
  **History of infections requiring hospitalization**                                           5378      36.9          1.06 (1.03--1.08)   8299    33.1         0.94 (0.92--0.97)   12116   35.6         1.00 (ref)
  **Obesity**                                                                                   4468      30.7          1.60 (1.55--1.66)   6365    25.4         1.45 (1.40--1.49)   5653    16.6         1.00 (ref)
  **Alcoholism**                                                                                155       1.1           0.85 (0.70--1.02)   233     0.9          0.71 (0.61--0.83)   444     1.3          1.00 (ref)
  **Mental Disorders**                                                                          7973      54.7          1.05 (1.03--1.07)   13096   52.2         1.01 (1.00--1.03)   17767   52.1         1.00 (ref)
  **Previous hypoglycaemia**                                                                    163       1.1           1.10 (0.92--1.31)   261     1.0          0.96 (0.83--1.12)   479     1.4          1.00 (ref)
  **Trombocyte aggregation prophylaxis**                                                        5091      34.9          1.18 (1.15--1.21)   9630    38.4         1.22 (1.20--1.25)   12306   36.1         1.00 (ref)
  **Statins**                                                                                   10672     73.2          1.07 (1.05--1.08)   19212   76.6         1.10 (1.09--1.11)   24466   71.8         1.00 (ref)
  **ACE inhibitors**                                                                            5425      37.2          1.08 (1.05--1.11)   9529    38.0         1.07 (1.05--1.10)   12576   36.9         1.00 (ref)
  **ATII antagonists**                                                                          4907      33.7          1.22 (1.19--1.25)   8781    35.0         1.24 (1.21--1.27)   10385   30.5         1.00 (ref)
  **Any antihypertensive treatment**                                                            11458     78.6          1.10 (1.09--1.11)   20024   79.9         1.09 (1.08--1.10)   26629   78.1         1.00 (ref)
  **Oral steriods**                                                                             909       6.2           0.94 (0.88--1.01)   1376    5.5          0.80 (0.75--0.85)   2713    8.0          1.00 (ref)
  **Marital status**                                                                                                                                                                                      
  Divorced                                                                                      2519      17.3          1.08 (1.04--1.13)   4214    16.8         1.06 (1.03--1.10)   5461    16.0         1.00 (ref)
  Married                                                                                       8019      55.0          1.01 (0.99--1.03)   14464   57.7         1.03 (0.98--1.08)   19011   55.8         1.00 (ref)
  Unknown                                                                                       178       1.2           0.83 (0.70--0.99)   197     0.8          1.06 (1.02--1.10)   422     1.2          1.00 (ref)
  Unmarried                                                                                     2738      18.8          1.06 (1.01--1.10)   4196    16.7         1.04 (1.03--1.06)   4604    13.5         1.00 (ref)
  Widowed                                                                                       1117      7.7           1.08 (1.01--1.14)   1999    8.0          0.57 (0.48--0.67)   4581    13.4         1.00 (ref)
  **Median baseline % HbA**~**1c**~ **(IQR)** [‡](#t001fn002){ref-type="table-fn"}              8.4       (7.5--9.5)                        8.3     (7.5--9.4)                       7.8     (7.2--8.8)   
  **Median baseline eGFR ml/min/1.73m**^**2**^ **(IQR)** [‡](#t001fn002){ref-type="table-fn"}   87        (62--100)                         89      (73--106)                        82      (62--100)    
  **Median baseline LDL mmol/L (IQR)** [‡](#t001fn002){ref-type="table-fn"}                     2.0       (1.5--2.6)                        1.9     (1.6--2.5)                       2.0     (1.6--2.7)   

^†^ Charlson Comorbity level calculated as a total score of 0, 1, 2 or 3 and more.

^‡^ Numbers based on the North and Central Denmark Regions (\~30% of total Danish population) where laboratory data were available.

^§^ Adjusted for differences in age and sex.

[Fig 3](#pone.0229621.g003){ref-type="fig"} shows time trends from 2014 Q1 to 2017 Q4 in the proportion of SGLT2i, GLP-1RA, and DPP-4i initiators who had established ASCVD and hospital-diagnosed obesity, respectively, at treatment initiation. For SGLT2i initiators, the proportion with any ASCVD increased slightly from 28% in 2014 to 30% in 2017, partly related to increasing patient age over time, which corresponded to an aPR of 1.03 (95% CI: 0.97--1.10) in 2017, as compared with the first study year 2014 ([S1 File](#pone.0229621.s001){ref-type="supplementary-material"}). A slight increase in ASCVD since 2015 was seen in parallel in the two major groups of empagliflozin and dapagliflozin initiators, with the ASCVD proportion continuously being about 5 percentage points higher in empagliflozin than in dapagliflozin starters ([S1 File](#pone.0229621.s001){ref-type="supplementary-material"}). For GLP-1RA initiators, the ASCVD proportion was 29% in 2014 versus 27% in 2017 (aPR in 2017: 0.90 (95% CI: 0.84--0.97)) ([S1 File](#pone.0229621.s001){ref-type="supplementary-material"}). For DPP-4i initiators ASCVD also decreased slightly, from 31% to 29% (aPR in 2017: 0.91 (95% CI: 0.88--0.96) ([S1 File](#pone.0229621.s001){ref-type="supplementary-material"}). For SGLT2i initiators, hospital-diagnosed obesity declined from 29% to 24% while prevalence of obesity among GLP-1RA initiators increased from 27% to 32% ([Fig 3](#pone.0229621.g003){ref-type="fig"}). Prevalence of obesity among DPP4i initiators increased over the study period from 16% (2014) to 19% (2017), but remained clearly lower, compared to SGLT2s and GLP1 initiators.

![Time trends in proportions with established atherosclerotic cardiovascular disease (ASCVD) or hospital-diagnosed obesity at baseline.\
Obesity: used hospital inpatient and outpatient contacts. ASCVD: atherosclerotic cardiovascular disease; DPP-4i: dipeptidyl peptidase-4 inhibitor; GLP-1RA: glucagon-like peptide-1 receptor agonists; SGLT2i: sodium-glucose cotransporter 2 inhibitors; TECOS: Sitagliptin (DPP-4i) showed non-inferiority to placebo \[[@pone.0229621.ref035]\]; Lira obesity label: Liraglutide 3 mg launched as treatment for obesity; EMPA-REG OUTCOME: empagliflozin showed CV and CV/all-cause mortality benefits \[[@pone.0229621.ref010]\], LEADER: liraglutide showed CV and CV/all-cause mortality benefits \[[@pone.0229621.ref012]\]; CANVAS: canagliflozin showed CV benefits \[[@pone.0229621.ref011]\].](pone.0229621.g003){#pone.0229621.g003}

[Fig 4](#pone.0229621.g004){ref-type="fig"} shows time trends from 2014 Q1 to 2017 Q4 in the proportion of SGLT2i, GLP-1RA, and DPP-4i initiators who had acute myocardial infarction (AMI) and heart failure (HF), respectively, diagnosed prior to treatment initiation. For SGLT2i initiators, the proportion with any ischemic heart disease increased from 19% in 2014 to 22% in 2017, corresponding to an aPR of 1.10 (95% CI 1.01--1.19) in 2017 versus 2014 ([S1 File](#pone.0229621.s001){ref-type="supplementary-material"}). In contrast for GLP-1RA initiators and DPP-4i initiators, ischemic heart disease decreased slightly over time ([S1 File](#pone.0229621.s001){ref-type="supplementary-material"}). Similarly for established heart failure, the prevalence among SGLT2i initiators increased over time, from 5% to 7% (aPR 1.22 (95% CI 1.03--1.45)), while heart failure among GLP1-1RA and DPP-4i initiators decreased slightly. [S1 File](#pone.0229621.s001){ref-type="supplementary-material"} shows time trends from 2014 Q1 to 2017 Q4 in the proportion of SGLT2i, GLP-1RA, and DPP-4i initiators who had redeemed a prescription for antihypertensive drugs and statins 12 months prior to initiation. While the proportion with antihypertensive drug use was rather stable, the proportion using statins showed a declining tendency, especially in GLP-1RA initators.

![Time trends in patient proportions with acute myocardial infarction (AMI), heart failure (HF), or stroke at baseline.\
AMI: acute myocardial infarction; HF: heart failure; DPP-4i: dipeptidyl peptidase-4 inhibitor; GLP-1RA: glucagon-like peptide-1 receptor agonists; SGLT2i: sodium-glucose cotransporter 2 inhibitors; TECOS: Sitagliptin (DPP-4i) showed non-inferiority to placebo \[[@pone.0229621.ref035]\]; Lira obesity label: Liraglutide 3 mg launched as treatment for obesity; EMPA-REG OUTCOME: empagliflozin showed CV and CV/all-cause mortality benefits \[[@pone.0229621.ref010]\], LEADER: liraglutide showed CV and CV/all-cause mortality benefits \[[@pone.0229621.ref012]\]; CANVAS: canagliflozin showed CV benefits \[[@pone.0229621.ref011]\].](pone.0229621.g004){#pone.0229621.g004}

Discussion {#sec016}
==========

In this real-life clinical care study, we observed many similarities in baseline patient characteristics between SGLT2i and GLP-1RA initiators, while differentially evolving time trends were observed for therapy lines of SGLT2i and GLP-1RA. Moreover, among SGLT2i initiators the proportions with established ASCVD or heart failure increased slightly between 2014 and 2017, while these proportions remained stable or decreased slightly among initiators of GLP-1RA or DPP-4i.

Interpretation {#sec017}
--------------

### Incidence {#sec018}

The much higher rise in incidence of SGLT2i versus GLP-1RA initiation during 2014 to 2017 may reflect that SGLT2i was a new drug class on the market in 2014, as compared with GLP-1RA being an established T2D treatment already at the beginning of our study period. Thus, when comparing new users of the three drug classes, SGLT2i increased from the least prescribed drug class per 100,000 and to the most prescribed drug class in only 3 years. Notably, following the positive CV outcome trial EMPA-REG OUTCOME in 2015 Q3 there was a large increase in the overall prescription of SGLT2i, continuing an increasing SGLT2i trend seen already before 2015 Q3, yet primarily related to distinct increase in empagliflozin use after 2015 Q3. Since the national diabetes guidelines were not changed during the study time period, this increase could be driven by the published CV outcome trial results and to some extend the following CV label updates. A similar jump in increase was not observed for GLP-1RA or liraglutide following the positive CV outcome trial LEADER in 2016 Q3, i.e., for GLP-1RA the incidence increase over time was more modest and steady. In a sensitivity analysis, inclusion of liraglutide 3.0 mg daily (obesity treatment label) in our incidence analyses slightly raised the GLP-1RA initiation incidence trend. In addition to the difference in time at market, the lower rise in new prescriptions among GLP1-RA may also reflect the difference in drug administration (oral vs injectable).

Despite increased use of the newer drug classes (SGLT2i and GLP1-RA) and the documented 10% annual decline in incidence of T2D in Denmark since 2012 \[[@pone.0229621.ref027]\], the DPP4i class initiation did not decline. This may be due to a generally increased focus on timely and earlier treatment intensification with add-on therapies for good glycemic control, supported by updated guidelines \[[@pone.0229621.ref015],[@pone.0229621.ref028]\].

As a side finding, we observed that all drug classes saw an incidence decline in all Q3s, presumably an effect from widespread summer vacations in the Danish healthcare system July-August, with expected fewer planned patient therapy changes.

### Treatment lines {#sec019}

We found that treatment lines of GLP-1RA initators remained relatively stable throughout the period. During this time, the use of SGLT2i as second line therapy increased markedly. This was corroborated by recent US findings by Montvida et al, demonstrating a fast SGLT2i adaptation constituting 7% of all second line drugs used in 2016 versus 0% in 2013, while GLP-1RA as second-line drug increased from 5% to 7% \[[@pone.0229621.ref029]\].

### CVD prevalence {#sec020}

In Denmark, 20% to 25% of patients with early type 2 diabetes have ASCVD \[[@pone.0229621.ref030],[@pone.0229621.ref031]\]. This is less than observed in either of the drug initiation classes we examined, which may be due to the majority of patients in our study study having a diabetes duration of at least 5 to 8 years together with a clinical decision of adding a subsequent drug class. Following the CV outcome trials for SGLT2i, some of the differences between characteristics of SGLT2i and DPP4i initiators diminished. When adjusting for higher age among DPP-4i initiators (and thus taking into account the expected age-related increase in comorbidities), we did find a slightly higher CV disease prevalence among SGLT2i and GLP-1RA users. Of note however, according to updated treatment guidelines \[[@pone.0229621.ref015],[@pone.0229621.ref016]\] also patients with advanced age and CVD would likely benefit from treatment with SGLT2i or GLP-1RA as compared with DPP-4i. Our findings are in line with a recent Danish study, finding that presence or absence of previous CVD had little effect on SU prescription likelihood during 2006--2012 despite the potential CVD risk associated with use of SUs \[[@pone.0229621.ref032]\]. Specifically for GLP-1RA initators, the lower crude prevalence of many CV conditions may in part be attributed to liraglutide being used more often in women related to its weight-reducing effect, with middle-aged women in general having lower risk of CV disease versus men.

Strengths and limitations {#sec021}
-------------------------

All antihyperglycemic drugs require prescriptions by a physician in Denmark and are partially reimbursed, making our drug utilization coverage close to complete on a population-based nationwide level, minimizing the risk of selection bias in the identification of patients with T2D often seen in other clinic-based studies. We have recently found evidence for high positive predictive values of the CV diagnoses used in the present study (e.g., myocardial infarction: 97%, heart failure: 76%, stroke: 97%) \[[@pone.0229621.ref021],[@pone.0229621.ref033]\]. We defined the term ASCVD used in recent diabetes guidelines as either ischemic heart disease (composed of unstable angina \[PPV: 46%\], myocardial infarction \[PPV: 97%\] or other ischemic heart disease \[unknown PPV\]), cerebrovascular disease \[PPV: 97%\], abdominal or peripheral vascular disease \[PPV 100%\]), while keeping heart failure \[PPV 76%\] as a separate category \[[@pone.0229621.ref021],[@pone.0229621.ref034]\]. The PPV of obesity diagnosis is unkown but presumably high, although underrecording of obesity is likely. Since any misclassifications of these diseases is unlikely related to which antihyperglycemic drug class a patient uses, this is unlikely to have major impact on our findings.

Conclusions {#sec022}
===========

The current study provides evidence for some dynamics in the use of SGLT2i and GLP-1RAs (increase in overall use for both drug classes; increase in 2^nd^ line therapy use for SGLT2i), with remarkably little changes by now in the characteristics including CVD prevalences of patients intiating these drugs. If physicians had closely followed the newest clinical trial results and adapted their T2D treatment accordingly, increasing initiation of SGLT2is and GLP-1RAs among T2D patients with prevalent CVD could be expected \[[@pone.0229621.ref015]\] (with opposite findings for new DPP4i users). Our findings may indicate that physicians caring for T2D patients in real life are impacted by recent new and convenient HbA1c-lowering treatment options, but until now only to a limited extent have considered presence or absence of CVD in their treated patients. Thus, the large increase in SGLT2i and GLP-1RAs utilization may relate to generally increased clinician knowledge and awareness of effectiveness and safety of these newer drug classes in recent years, and thus more confidence in prescribing. Physicians may in addition have considered the drug effect on other clinically relevant parameters such as magnitude of HbA~1c~ reduction, as well as CV risk factors including body weight and blood pressure. It will be interesting to follow how user characteristics may change after the recently updated national \[[@pone.0229621.ref015]\] and international guidelines \[[@pone.0229621.ref014],[@pone.0229621.ref016]\], which clearly guide treatment choices not only based on HbA1c level and CV risk factors including weight and blood pressure, but also more specifically on preexisting CVD including heart failure and kidney impairment.

In conclusion, following the EMPA-REG OUTCOME trial SGLT2i were increasingly used as 2nd-line treatment in everyday clinical practice, with only minor increases in proportions with ASCVD over time. For GLP-1RA, proportions with ASCVD have decreased, despite publication of the LEADER trial. Recently updated guidelines for T2D patients with ASCVD and heart failure/ renal impairment may affect these real-world trends in the future.

Supporting information {#sec023}
======================

###### 

(DOCX)

###### 

Click here for additional data file.

ASCVD

:   atherosclerotic cardiovascular disease

ATC

:   Anatomical Therapeutic Chemical

CCI

:   Charlson comorbidity index

CI

:   Confidence Interval

CPR

:   Central Personal Registry

CRS

:   Civil Registration System

CV

:   cardiovascular

DNPR

:   Danish National Patient Register

DPP-4i

:   dipeptidyl peptidase 4 inhibitors

GLP-1RAs

:   glucagon-like peptide-1 receptor agonists

HF

:   Heart failure

ICD-10

:   International Statistical Classification of Diseases and Related Health Problems 10^th^ revision

MI

:   Myorcardial Infarction

Q

:   Quarter

SGLT2i

:   Sodium-glucose co-transporter 2 inhibitors

T2D

:   type 2 diabetes
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We note that one or more of the authors are employed by a commercial company: name of commercial company.

1\. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Response:

The statement now reads:

"Sources of funding: This work was supported by an institutional research grant from Boehringer Ingelheim to Aarhus University. While Boehringer Ingelheim was involved in the study's concept, it was designed and conducted by the coauthors from Aarhus University. The funder provided support in the form of salaries for authors ML, LN, and AU, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. "

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

Response:

Please see our response above.

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

Response:

Please see our response above.

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Response:

We have included an amended text reading:

"Conflict of interest disclosures: ML, LN and AU are employees of Boehringer Ingelheim. The other authors have no personal conflicts of interest relevant to this article. The Department of Clinical Epidemiology is involved in studies with funding from various companies as research grants to (and administered by) Aarhus University. The commercial affiliation did not alter our adherence to PLOS ONE policies on sharing data and materials. However, Danish law does not allow researchers to share raw data from the registries with third parties. Data can be accessed by researchers through application to the Danish Data Protection Agency and the Danish Health Data Authority."

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

Response:

Please see our response above.

4\. Please ensure that you refer to Figure 4 in your text as, if accepted, production will need this reference to link the reader to the figure.

Response:

The manuscript reads: "Fig 4 shows time trends from 2014 Q1 to 2017 Q4 in the proportion of SGLT2i, GLP-1RA, and DPP-4i initiators who had acute myocardial infarction (AMI) and heart failure (HF), respectively, diagnosed prior to treatment initiation."

5\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

Response:

We have included captions for Supporting Information at the end of the manuscript. We have renamed and renumbered tables and figures in the supplementary and updated the manuscript accordingly.

Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This paper, describing prescription patterns of anti diabetic drugs, presents new research of both local and general interest. It is methodologically sound and falls within the scope of PLOSone.

Response:

We thank the reviewer for finding our study both interesting and sound.

In brief, the authors focus on the impact of recent CVOTs demonstrating cardioprotective effects of SGLT-2 inhibitors and GLP-1 analogues. They describe first use of these drugs according to patient characteristics (a stable prevalence of CVD) and the appearance of publications and conclude that, in particular the EMPAreg study, CVOTs impact prescription patterns.

A few points for the author\'s considerations:

Is the impact of EMPA-reg really substantiated for the use of SGLT-2 inhibitors as stated (the slope of the curve in Fig1 appears to be exactly the same before and after publication of the EMPAreg)? The shift seems to be a larger proportion of empagliflozin (vs dapagliflozin).

Response:

We fully agree with the reviewer that, when considering fig 1 in isolation, it is visually less clear if there is a major change in the prescription incidence trend of SGLT2i overall. When considering S2 fig, we believe it more clearly shows an increase in the slope in SGLT2i prescription trends, solely driven by large increases in empagliflozin initiation.

We have now modified the statements in the manuscript describing the changes following EMPA-REG outcome. As we wrote on page 14, "Notably, following the positive CV outcome trial EMPA-REG OUTCOME in 2015 Q3 there was a distinct and large increase in the prescription of SGLT2is, primarily related to increase in empagliflozin use.".

The authors might briefly discuss the original design and intended impact of CVOTs (primarily safety trials) and maybe also state that a negative impact of trials can be seen as well; the authors themselves have described negative impacts of trials on prescription patterns (BMJ Open. 2013 Sep 24;3(9):e003424).

Response:

We thank the reviewer for having read the previous publication and for pointing out that the purpose of CVOTs may not be fully clear from the manuscript. We have updated the manuscript accordingly:

"In the most recent years, the prescription patterns of SGLT2i and GLP-1RAs in real-world settings may have been increasingly influenced by landmark cardiovascular (CV) outcome trials instigated by regulatory authorities to promote patient safety \[9\],"

The total number of users of GLP-1 analogues and SGLT2 inhibitors during the period would be of interest.

Response:

We agree. We have now included these data in the beginning of the Results:

"We identified 25,070 new first-time SGLT2i initiators, 14,671 first-time GLP-1RA initiators, and 34,079 first-time DPP-4i initiators in Denmark during 2014-2017. As a point of comparison, the total number of unique prevalent users in Denmark during 2014-2017 was 32,091 for SGLT2i, 37,282 for GLP-1RA, and 64,613 for DPP-4i (data not shown)."

Since previous CVD does not appear to be the driver for prescription of drugs with a potential benefit (well-known also for SUs, Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):606-61), could the authors identify or even quantify more marketing-related mechanisms which would most likely also influence the pattern?

Response:

We thank the reviewer for pointing out the interesting study in BCPT, which may corroborate our findings that clinical considerations about pre-existing CVD or not may not be the main or only driver for the choice of prescription.

We have updated our discussion section with the reference and a remark including this important aspect. "Our findings are in line with a recent Danish study, finding that presence or absence of previous CVD had little effect on SU prescription likelihood during 2006-2012 despite the potential CVD risk associated with use of SUs \[32\]."

Identifying the exact marketing-related mechanisms that are most likely to have resulted in the increase in adaptation would indeed be valuable, however, it is beyond the scope of this paper, and unfortunately also beyond the data available in our dataset.

We have included the following sentence: "Thus, the large increase in SGLT2i and GLP-1RAs utilization may relate to generally increased clinician knowledge and awareness of effectiveness and safety of these newer drug classes in recent years, and thus more confidence in prescribing."

Finally, check the language, e.g. a lot of of\'s in lines 17-18, p3.

Response:

We thank the reviewer for pointing this out and have revised the language.

Reviewer \#2: Jakob et al. present nationwide changes in clinical characteristics of initiators of SGLT2i and GLP-1RA, the relatively new class of medicine for type 2 diabetes treatment, and found an increased usage of SGLT2i, especially empagliflozin, around the publish of EMPAREG-OUTCOME trial, while GLP-1RA therapy lines are stable around LEADER trial. Moreover, the authors found that improved CV outcomes in those trials did NOT lead to increase the proportion of target patient from the trial. The study is well-designed, including the enough number of patients, and of interest for the researchers in the field of diabetics and economics.

Response:

We thank the reviewer for finding our study well-designed and interesting.

However, there are several concerns to clarify before published.

Major

1\. In p12 author discuss, "Notably, following the positive CV outcome trial EMPA-REG OUTCOME in 2015 Q3 there was a distinct and large increase in the prescription of SGLT2is"

However, the tendency of the whole SGLT2is' prescriptions between before and after the publish of EMPAREG-OUTCOME trial seems not so changed in the figure. SGLT2is' initiators seem linearly increasing throughout 2014-2017. As authors pointed out in p13, an incidence decline in all Q3s makes difficult to read the effect of EMPAREG-OUTCOME. So, proof by quantitative evaluation between before and after initiation the trial is needed. Causal relationship might be difficult to be proved, but that data helps our interpretation. e.g. if the number of SGLT2is initiation is not relating to that trial, there are no wonder even the proportion of ASCVD is not increased.

Response:

We fully agree with the reviewer that, when considering fig 1 in isolation, it is visually less clear if there is a major change in the prescription incidence trend of SGLT2i overall after 2015, or if there is merely a continuously increase in SGLT2i incidence throughout the entire study period.

When considering S2 fig, we believe it more clearly shows an increase in the slope in SGLT2i prescription trends, solely driven by large increases in empagliflozin initiation after 2015.

We have now modified the statements in the manuscript describing the changes following EMPA-REG outcome, to make them more precise. "Notably, following the positive CV outcome trial EMPA-REG OUTCOME in 2015 Q3 there was a large increase in the overall prescription of SGLT2i, continuing an increasing SGLT2i trend seen already before 2015 Q3, yet primarily related to distinct increase in empagliflozin use after 2015 Q3."

We also agree that SGLT2i trends obviously may be affected by other factors than a CVOT, and we have now included the following note in the Discussion section: "Thus, the large increase in SGLT2i and GLP-1RAs utilization may relate to generally increased clinician knowledge and awareness of effectiveness and safety of these newer drug classes in recent years, and thus more confidence in prescribing."

2\. Is there any change in ASCVD proportion between empagliflozin and other SGLT2is initiators after the EMPAREG-OUTCOME trial?

Response:

Below we have created the figure 3 ASCVD panel, restricted to SGLT2i and stratified by individual drug types in order to address this question. We observe a slight increase since the time of the EMPAREG OUTCOME trial in the proportion with ASCVD for both dapagliflozin and empagliflozin initiators (canagliflozin starters are too few to yield statistically reliable trends). The ASCVD proportion was about 5 percentage points higher in empagliflozin than in dapagliflozin starters. This ASCVD difference between the 2 drugs was rather constant over time, and the difference was visible already before the EMPAREG outcome trial and not clearly affected by the trial publication.

We have added to the manuscript Results: "A slight increase in ASCVD since 2015 was seen in parallel in the two major groups of empagliflozin and dapagliflozin initiators, with the ASCVD proportion continuously being about 5 percentage points higher in empagliflozin than in dapagliflozin starters (data not shown).

3\. In Figure3, there is a drop down about ASCVD proportion of SGLT2i initiators and reciprocal increase of GLP-1RA in 2015Q3. Isn't there any comment?

Response:

We agree with the reviewer that these apparent "outliers" in 2015Q3 seem a bit remarkable, especially considering the timing co-incident with the EMPA-REG outcome trial publication. We have also discussed this finding. Both curves (for GLP-1RA and SGLT2i) in the following quarter show compensatory ASCVD changes back to more "normal" values, leading to ASCVD proportions that -- if taking an average over the six months (2015-Q3+2015-Q4) - would be completely in alignment with the overall curve trends. Moreover, we find it less clinically plausible that, over just half a year, we would see first temporary pre-trial changes that are then fully reversed in the following quarter, all as a consequence of the trial. There is some statistical variation seen from quarter to quarter, and we think the "extreme" values coinciding with one data point in 2015Q3 should probably be regarded as outliers, with some regression towards the mean observed in the following quarters.

4\. In Japan (my country), there is an alert from the committee of japan diabetes society for the risk of SGLT2i, e.g. about dehydration leading to cerebrovascular infarction, especially in the elderly. I think the result of EMPAREG-OUTCOME gave the great relief on the doctors to prescribe widely (although it is mere speculation) because even patients with the most CV risks are safe for the SGLT2i initiation. Please describe the policies and guidelines applied to Danish diabetic patients concerning the study, for readers outside Denmark.

Response:

We thank the reviewer for pointing out that it is not unambiguously clear from the manuscript that the Danish guidelines has been and are following the international guidelines closely. We have updated the manuscript to reflect this. The manuscript now reads:

"While metformin has remained the recommended initial antihyperglycemic drug for most patients with T2D, international (and Danish) guidelines until now have recommended a free choice among several second or third line treatment options, based on an individualised treatment approach \[8\]. In the most recent years, the prescription patterns of SGLT2i and GLP-1RAs in real-world settings may have been increasingly influenced by landmark cardiovascular (CV) outcome trials instigated by regulatory authorities to promote patient safety \[9\], but data on incident utilization trends are scarce. In 2015, the empagliflozin EMPA-REG OUTCOME trial \[10\] showed a reduced risk of CV outcomes, CV mortality, and all-cause mortality in patients with T2D with existing CV disease. In 2017, the canagliflozin CANVAS trial program \[11\] showed a reduced risk of major adverse CV events in patients with T2D and high CV risk. For GLP-1RAs, the 2016 liraglutide LEADER trial showed a reduced risk of CV outcomes, CV mortality, and all-cause mortality in patients with high CV risk. A reduced risk of CV outcomes was also observed in similar patients receiving semaglutide in the SUSTAIN-6 trial in 2016 \[12,13\]. Therefore, in the most recent updates to the EASD/ADA and Danish guidelines from 2018 and 2019 \[14--16\], initiation of a SGLT2i or a GLP-1RA with proven CV benefit has been recommended for patients with T2D and clinical CV disease, with currently strongest evidence available for liraglutide and empagliflozin \[14--16\]."

Minor

Please check the following

p1 Author name jakob s -\>Jakob S.

p11 (95%CI 1.01.1.19)-\>1.01-1.19

Response: We thank the reviewer and have corrected the errors.
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We would appreciate receiving your revised manuscript by Mar 15 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.
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The first instance we have simply revised the manuscript that we have made a comparison using an analysis on our own data. The manuscript now reads:

"As a point of comparison, the total number of unique prevalent users in our data during 2014-2017 was 32,091 for SGLT2i, 37,282 for GLP-1RA, and 64,613 for DPP-4i."

In the second instance, we referred to an analysis performed and presented during the review process, but not included in the manuscript previously. We have now revised the manuscript, adding this to the supplementary and updating the remaining documents accordingly.
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